Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

The Multi-Heart Plate: a human engineered mini-heart platform for functional cardiac disease modelling and drug testing

Ziel

Cardiovascular diseases remain a leading cause of mortality worldwide, yet drug development is hampered by the lack of predictive human models that capture cardiac function. In particular, diastolic dysfunction and heart failure with preserved ejection fraction represent major unmet medical needs, partly because current preclinical models inadequately reproduce human cardiac physiology. This HEARTPUMP project aims to explore the innovation potential of the Multi-Heart Plate (MHP), a novel human stem cell-based platform developed in the ERC Advanced Grant HEART2BEAT. The MHP consists of miniature engineered cardiac chambers capable of pumping fluid and generating quantitative functional readouts such as cardiac output, ejection fraction and relaxation kinetics. This enables direct assessment of cardiac performance and drug responses in a physiologically relevant human model. HEARTPUMP will combine technical validation and commercial feasibility activities. Technically, we will demonstrate the reproducibility and robustness of the platform, develop and validate a diastolic dysfunction disease model, and establish a drug screening portfolio to benchmark predictive performance against existing models. Workflow optimization, including automated data analysis and assay standardization will further improve scalability and usability for drug discovery. In parallel, we will engage with pharmaceutical and biotechnology companies and contract research organizations to assess industry requirements and obtain early feedback. Intellectual property strategy and market analysis will be conducted with technology transfer experts to evaluate commercial opportunities and guide the development of a business plan. Together, these activities will demonstrate the technical and commercial feasibility of the MHP platform and establish the basis for its translation into cardiovascular drug discovery, potentially through creation of a spin-out company or alternative commercialization pathways.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

UNIVERSITEIT TWENTE
Netto-EU-Beitrag
€ 150 000,00
Adresse
DRIENERLOLAAN 5
7522 NB Enschede
Niederlande
Region
Oost-Nederland Overijssel Twente
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Begünstigte (1)